loading

Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten

pulisher
04:02 AM

Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

04:02 AM
pulisher
Mar 03, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Mar 03, 2026
pulisher
Mar 02, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat

Mar 02, 2026
pulisher
Feb 24, 2026

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail

Feb 24, 2026
pulisher
Feb 23, 2026

Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks

Feb 23, 2026
pulisher
Feb 13, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat

Feb 13, 2026
pulisher
Feb 11, 2026

Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz

Feb 11, 2026
pulisher
Feb 09, 2026

Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks

Feb 09, 2026
pulisher
Feb 06, 2026

Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks

Feb 06, 2026
pulisher
Feb 05, 2026

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewswire Inc.

Feb 05, 2026
pulisher
Feb 05, 2026

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm

Feb 05, 2026
pulisher
Jan 31, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail

Jan 31, 2026
pulisher
Jan 30, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jan 30, 2026
pulisher
Jan 30, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World

Jan 30, 2026
pulisher
Jan 17, 2026

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail

Jan 17, 2026
pulisher
Jan 17, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World

Jan 17, 2026
pulisher
Jan 15, 2026

Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks

Jan 15, 2026
pulisher
Jan 14, 2026

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - markets.businessinsider.com

Jan 14, 2026
pulisher
Jan 14, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jan 14, 2026
pulisher
Jan 14, 2026

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail

Jan 14, 2026
pulisher
Jan 09, 2026

LENZ Therapeutics (LENZ) Receives a Buy from Piper Sandler - The Globe and Mail

Jan 09, 2026
pulisher
Jan 08, 2026

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jan 08, 2026
pulisher
Jan 07, 2026

Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks

Jan 07, 2026
pulisher
Jan 06, 2026

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm

Jan 06, 2026
pulisher
Dec 23, 2025

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World

Dec 23, 2025
pulisher
Dec 22, 2025

Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat

Dec 22, 2025
pulisher
Dec 17, 2025

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks

Dec 17, 2025
pulisher
Dec 16, 2025

Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN

Dec 16, 2025
pulisher
Dec 10, 2025

Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail

Dec 10, 2025
pulisher
Dec 09, 2025

Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN

Dec 09, 2025
pulisher
Dec 08, 2025

Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - TipRanks

Dec 08, 2025
pulisher
Dec 05, 2025

Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView

Dec 05, 2025
$45.38
price down icon 4.20%
$29.39
price down icon 0.44%
$53.73
price down icon 6.90%
$103.05
price down icon 0.96%
$144.01
price down icon 4.01%
biotechnology ONC
$293.34
price down icon 1.97%
Kapitalisierung:     |  Volumen (24h):